SUMMARY A total of 398 cases of B cell lymphoproliferative disease were phenotypically characterised by membrane mouse red blood cell (MRBC) receptor, surface immunoglobulin, common acute lymphoblastic leukaemia (CALLA), and FMC7 and Ti monoclonal antibody studies. Relations between chronic lymphocytic leukaemia (CLL), prolymphocytic leukaemia (PLL), and "prolymphocytoid" CLL variants were examined with particular reference to the expression of FMC7. In addition, the reactivity of TUI monoclonal antibody with B cell disorders was established. The results suggest that despite some heterogeneity most cases may be characterised by their phenotypic patterns and that these investigations provide a reproducible basis for classification.
Immunological studies in lymphoproliferative disease have been well documented. Although a greater understanding of the relation between phenotypic patterns and stages of cellular differentiation has been gained, the potential value of immunological characterisation is often limited by the small numbers of patients examined or the unavailability of some monoclonal reagents. One of the principal aims of phenotypic studies is to provide a fundamental basis for classifying lymphoproliferative disorders into prognostically relevant and reproducible groups. A prerequisite for such schemes is that the antisera used must be well characterised and widely available. Taking these factors into account, we reviewed the phenotypic patterns of B cell lymphoproliferative disorders referred to this department over the past two years and present here the results obtained with commercially available antisera for expression of surface immunoglobulin (SIg), common acute lymphoblastic leukaemia antigen (CALLA, J5), FMC7, TUl, and Ti.
Patients and methods
IMMUNOLOGICAL STUDIES
Lymphocytes were fractionated from peripheral blood or bone marrow samples by density sedimentation with Lymphoprep (Nyegaard). Expression of membrane mouse red blood cell (MRBC) receptors Accepted for publication 16 May 1985 was determined with CBA murine erythrocytes using standard procedures. ' 2 Lymphocytes and MRBC were tested without first being treated with neuraminidase. The expression of SIg K or X light chains was investigated with polyclonal (Dako) or monoclonal (Unipath) reagents. The fluorescent intensity of cells positive for SIg, considered to be an empirical measure of the membrane density was subjectively assessed in each case and scored negative, weak, weak to moderate, or moderate to strong. Studies of SIg were confined to showing the presence of light chain monoclonality and the establishment of membrane density. Investigations of the expression of heavy chain were not routinely performed owing to their apparent diagnostic inconsistency. A total of 242 cases of B lymphoproliferation were examined for expression of the TU 1 determinant (Table 4) . Of the 175 cases of CLL, 157 showed high proportions (>70%) of positive cells. The expression of TU1 in these cases was usually weak, although 28 (16%) cases showed stronger staining. Of the remaining cases, 17 showed a small but significant proportion of weak positive cells and only one case was found to be unreactive. In contrast, 25 out of 42 of the cases of non-Hodgkin's lymphoma were negative. When these cases were further subdivided into subgroups defined by CALLA it was found that 72% of the CALLA negative cases were TU1 negative compared with 41% for the CALLA positive lymphomas.
In the group with PLL 12 of 18 were TUl negative. This was in contrast to the CLL-pro variants, which all expressed TU 1. Only seven cases of "hairy cellr leukaemia were examined in this part of the study; all were TUl negative.
The presence of membrane TU1 and Ti determinants in non-Hodgkin's lymphoma was further evaluated with regard to expression of CALLA and FMC7. In this analysis 54 cases of non-Hodgkin's lymphoma were subdivided into the following subgroups: CALLA negative and FMC7 negative; CALLA positive and FMC7 negative; CALLA negative and FMC7 positive; and CALLA positive and FMC7 positive. When the expression of TUl and Ti was examined in these phenotypic groups (Table 5) In the 28 cases of PLL studied 25 showed significant FMC7 positive components, two showed weak expression by 17% and 70% of cells, respectively, while the remaining case was FMC7 negative. All 14 cases of "hairy celr' leukaemia examined over the same period had high proportions of cells which expressed the FMC7 determinant strongly. FMC7 was also strongly expressed in five out of 12 (>80%) positive cells) of the group with CLL-pro. Of the remaining cases, five showed 30-73% weak to moderate positive cells, one showed 21 % weak to positive cells, and the other was FMC7 negative. 
